Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 3Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 90Lymphoid 68Myeloid 16Tumor-Agnostic 15Plasma cell 13Breast 13Gastrointestinal 12Thoracic 9Classical hematology 3Sarcoma 2Gynecologic 2Dermatologic 2CNS 2Head & Neck 1Genitourinary 1

Conditions

Prostatic Neoplasms 5016Carcinoma, Renal Cell 1574Urinary Bladder Neoplasms 1279Kidney Neoplasms 723Breast Neoplasms 642Neoplasms 628Carcinoma, Transitional Cell 487Neoplasm Metastasis 468Carcinoma, Non-Small-Cell Lung 467Melanoma 421Ovarian Neoplasms 399Colorectal Neoplasms 370Lung Neoplasms 333Pancreatic Neoplasms 262Sarcoma 231Stomach Neoplasms 226Uterine Cervical Neoplasms 223Testicular Neoplasms 215Non-Muscle Invasive Bladder Neoplasms 214Head and Neck Neoplasms 192Squamous Cell Carcinoma of Head and Neck 187Colonic Neoplasms 167Carcinoma, Hepatocellular 165Esophageal Neoplasms 164Endometrial Neoplasms 164Wilms Tumor 159Recurrence 131Triple Negative Breast Neoplasms 128Neuroblastoma 127Small Cell Lung Carcinoma 125

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasm, Residual × Genitourinary × Clear all
NCT03441464 2022-02-25

Feasibility of the LUM Imaging System for Detection of Prostate Cancer

Lumicell, Inc.

Phase 1/2 Terminated
9 enrolled
Genitourinary

Prostatic Neoplasms, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡